OncoMatch/Clinical Trials/NCT06525571
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Is NCT06525571 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Cysview and Karl Storz D-Light C Photodynamic Diagnostic (PDD) system for bladder cancer.
Treatment: Cysview · Karl Storz D-Light C Photodynamic Diagnostic (PDD) system — Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Excluded: Stage MUSCLE-INVASIVE BLADDER CANCER
high-risk non-muscle invasive bladder cancer
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sibley Memorial Hospital · Washington D.C., District of Columbia
- Johns Hopkins University School of Medicine · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify